Publication
Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260926-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMelanomacivic_curation1.00
- drugBinimetinibcivic_curation1.00
- geneNRAScivic_curation1.00
- variantNRAS Gaincivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-26
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29245078
- Run
- ING-CIVIC-20260926-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NRAS Amplification1 | ||||||||
| (prognostic) | Melanoma | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID13301In a retrospective cohort of 657 patients with melanoma, 92 (14.0%) had NRAS copy-number gain (>2 copies). Patients with NRAS gain had shorter median overall survival than patients with normal NRAS co… (full text at CIViC) PMID 29245078 · Yan et al., 2018 · Open in CIViC | civic |
| NRAS Gain2 | ||||||||
| (prognostic) | Melanoma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID13293In a retrospective cohort of 657 patients with melanoma, 92 (14.0%) had NRAS copy-number gain (>2 copies). Patients with NRAS gain had shorter median overall survival than patients with normal NRAS co… (full text at CIViC) PMID 29245078 · Yan et al., 2018 · Open in CIViC | civic |
| Binimetinib | Melanoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID6899In melanoma preclinical models, increased NRAS expression enhanced sensitivity to binimetinib in NRAS-copy-normal A875 cells, whereas NRAS knockdown decreased binimetinib sensitivity in NRAS-gain WM26… (full text at CIViC) PMID 29245078 · Yan et al., 2018 · Open in CIViC | civic |